At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Mar 8, 2026 at 18:00 ET
Dyne Therapeutics announced 24-month data from its Phase 1/2 DELIVER trial showing sustained functional improvements in heart and lung function for DMD patients treated with z-rostudirsen, a therapy targeting exon 51 skipping. The results, presented at the 2026 MDA Conference, suggest potential clinical benefits beyond muscle function, including cardiopulmonary improvements compared to natural history decline.
- 24-month data from the DELIVER trial show improvement in lung function (FVC%p), circumferential strain, and left ventricular ejection fraction vs. expected decline in natural history.
- Z-rostudirsen demonstrated a favorable safety profile with mostly mild or moderate TEAEs; no related serious adverse events in the registrational cohort.
- Therapy has FDA Breakthrough Therapy, Fast Track, and Rare Pediatric Disease designations for DMD amenable to exon 51 skipping.
- Most participants at 24 months were on lower doses than the registrational 20 mg/kg, suggesting potential for even greater efficacy at full dose.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access